-
Important speech at the two sessions!
Time of Update: 2021-03-22
Xi Jinping emphasized that at the critical moment of the fight against the new crown pneumonia epidemic, the majority of medical workers have lived up to the trust of the party and the people.
-
To Biao Qilu!
Time of Update: 2021-03-22
Source: official website of the State Food and Drug Administration, Mi Nei. com database Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
-
Hengrui Medicine Carrelizumab and Famitinib clinical trials approved by FDA
Time of Update: 2021-03-22
Up to now, the accumulated research and development expenses of carrelizumab for injection related projects are approximately RMB 1.
After inquiries, famitinib malate currently has sorafenib, sunitinib, pezopanib and other similar products approved for marketing at home and abroad.
-
Guangdong intraocular lens medical consumables price reduction multi-regional alliance members participate
Time of Update: 2021-03-21
Medical Network News on March 12 Multi-regional alliance members participate On March 8, the results of the proposed selection for volume procurement of intraocular lens medical consumables allianc
-
Is CDK4/6 inhibitor the next golden track in the field of breast cancer?
Time of Update: 2021-03-21
Figure 3 Annual sales of three CDK4/6 inhibitor drugs that have been on the market worldwide (100 million US dollars)Source: Pfizer, Novartis, Eli Lilly's annual reports, Zhongkang Industrial Capital Research CenterCompare the above three listed CDK4/6 inhibitor drugs for breast cancer treatment.
-
By 2021, retail pharmacies will face the most stringent inspections and penalties
Time of Update: 2021-03-21
cn/" target="_blank">and regulations and related quality management practices by pharmaceutical business enterprises, and conduct supervision and inspection of key varieties such as vaccines, special drugs, drugs selected for centralized procurement by the state, and Chinese herbal medicine pieces, purchase and sales channels, cold chain storage and transportation, "unified procurement and distribution", and personnel and other key aspects of performance of their duties, special drugs business enterprises , retail chain headquarters and other key enterprises, the implementation of key checks.
-
6 billion oseltamivir or competitor of welcome drug
Time of Update: 2021-03-21
Dongyang Sun Pharmaceutical actively enriches its product portfolioAs a major flu species with more than 6 billion yuan, the current application for oseltamivir is still hot, mainly for granules and capsules, as well as new dosage forms such as dry suspensions, sustained-release tablets, and orally disintegrating tablets.
-
Haisco's "Avanafil Tablets" will soon be approved for listing
Time of Update: 2021-03-21
Recently, the official website of the State Food and Drug Administration showed that Haisco’s application for the listing of avanafil tablets (acceptance numbers: CYHS1900563, CYHS1900564) submitted by registration classification 3 (domestic applicants imitated overseas listings but the original research was not listed domestically) has been At the "approval" stage, it is expected that the NMPA will approve the listing in the near future, and it will be the first imitation of this variety after listing.
-
Latest: All provinces report drug purchase plans!
Time of Update: 2021-03-21
In addition to the quantity purchased varieties, there are still a large number of varieties that will face the situation of direct listing, price linkage, group procurement, and special bargaining.
-
In 2020, the licensing cooperation between Chinese and foreign pharmaceutical companies is surging
Time of Update: 2021-03-21
The completion of the equity subscription enables the two parties to continue to advance a series of measures in the strategic cooperation framework, including Pfizer obtaining the exclusive authorization of CS1001, PD-L1 monoclonal antibody, the anti-tumor drug sugarizumab (CS1001, PD-L1 monoclonal antibody) in mainland China in the later stage of research and development of CStone Pharmaceuticals , CStone Pharmaceuticals received milestone payments of up to US$280 million and additional royalties.
-
Sichuan pharmaceutical company wins Novartis's over 2 billion cardiovascular varieties, the original research fails
Time of Update: 2021-03-21
Medical Network News, March 12, March 11, NMPA official website updated the drug approval information, Chengdu Better Pharmaceutical's Valsartan and Amlodipine Tablets (Ⅰ) 4 types of generic listing application was approved, the product is Better The first new product approved for the market this year.
-
Yifan Pharmaceutical's Recombinant Human Growth Hormone for Injection Approved for Clinical Trial
Time of Update: 2021-03-21
It is reported that F-899 is a long-acting recombinant human growth hormone (Growth Hormone, GH) new molecule designed and developed by the company’s holding subsidiary based on its unique DiKineTM molecular structure platform.
Compared with short-acting recombinant human growth hormone drugs, the half-life in vivo is significantly prolonged.
-
BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor
Time of Update: 2021-03-21
Source: Guanlan PharmaceuticalRecently, BeiGene announced that a phase 1 clinical trial of its in-development hematopoietic stem cell kinase 1 (HPK1) inhibitor BGB-15025 has completed its first patient administration.
In preclinical studies, inhibiting HPK1 can effectively promote T cell activation, thereby enhancing the anti-tumor activity of PD-1 inhibitors including BeiGene's Bezean (Tilelizumab).
-
Kelun, China Resources Double Crane, Hengrui lead!
Time of Update: 2021-03-21
Results of the selection of inter-provincial alliance drug centralized procurement 72%; height: 19px"> common name 9%; height: 19px"> Dosage form 6%; height: 19px"> specification 8%; height: 19px"> manufacturer 72%; height: 27px"> Compound amino acid (18AA) injection 9%; height: 27px"> Injection (large volume) 6%; height: 27px"> 250ml:12.
-
Procurement of medical consumables "3+N" with volume began to affect all distributors
Time of Update: 2021-03-21
In view of the fact that the relevant companies have been in accordance with the Tianjin Medical Purchasing Center's March 9th "Notice on Carrying out the Centralized Filling of Information on Coronary Dilatation Balloon Medical Consumables" Fill in the price information; The alliance’s regional research decided to introduce the reported price to the “3+N” Alliance of Beijing-Tianjin-Hebei “3+N” Alliance Coronary Dilation Balloon Medical Consumables Linkage Purchase Project.
-
A large number of varieties to meet the conditions of the fifth batch of collection (with list)
Time of Update: 2021-03-21
Medical Network News on March 15 With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
-
The pharmacy's strictest inspection and punishment is coming
Time of Update: 2021-03-21
Based on compliance inspections, they focus on purchasing drugs and recycling drugs through illegal channels; selling drugs beyond the scope of business; failing to store drugs in accordance with regulations , Transportation, temperature and humidity monitoring, tampering with computer system, temperature and humidity monitoring system data, concealing real drug purchase and sales records, bills, vouchers, and data; investigation of illegal behaviors such as non-compliance of prescription drug sales and "certification" of licensed pharmacists.
-
The highest drop is over 90%! The prices of some medicines and consumables in Heilongjiang Province have dropped significantly
Time of Update: 2021-03-21
Medical Network News, March 12, recently, the centralized procurement of drugs and coronary dilatation balloons organized by Heilongjiang, Sichuan, Jilin, Liaoning, Inner Mongolia, Shanxi, Hainan, Gansu, Tibet and other "six provinces and two regions" alliances is on schedule.
-
China Resources Double Crane was honored as one of the “Top 10 Employers with the Most Development Potential in Beijing in 2020”
Time of Update: 2021-03-21
It aims to select outstanding employers who can still give employees a sense of security and trust in the face of epidemic challenges and survival crises, and stimulate the symbiosis of organizational effectiveness and talents, and discuss In an uncertain era, how companies can use internal forces to counter the external environment and achieve safe and stable long-term development.
-
Procurement of 12 large varieties with volume will be implemented (list attached)
Time of Update: 2021-03-21
The results of the largest inter-provincial alliance's centralized procurement will soon be implemented, covering 11 provinces, 12 commonly used large varieties, and 31 pharmaceutical companies have successfully entered the market.
